Incyte (INCY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$3.60
- Estimate
- -$3.87
- Surprise
- +6.9%
- Revenue (period 2026-09-30)
- $1.56B
- Score at report (before → after)
- 6.9 → 5.8/10
Revenue source: xbrl.
How the report landed
Incyte (INCY) reported a narrower loss than forecast — adjusted EPS of -$3.60 against the -$3.87 estimate (a 6.9% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (6.9/10) to Hold at 5.8/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates INCY Buy (Wait) at 5.8/10.
3 of the last 4 quarters beat the estimate; this quarter's +6.9% surprise compares with a +20.0% four-quarter average. Next scheduled report: 2027-02-09.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Negative momentum
- Target reached (2.7% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $115.87
- Entry target
- $112.10
- Price target
- $119.03
- Stop
- $107.68
- Upside to target
- +2.7%
- Reward-to-risk
- 0.4:1
The stock trades at 60.1× trailing but 13.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
INCY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $24.01B
- P/E (fwd)
- 13.7
- P/E (ttm)
- 60.1
- 52-week range
- $89.25–$132.60
- Off 52-week high
- 12.6%
- RSI (14)
- 42
- Volume vs avg
- 0.67×
- Score today
- 5.8/10